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Abstract
Hyperphosphatemia is a common complication in dialysis-dependent patients with chronic kidney disease. Most dialysisdependent patients need oral phosphate binder therapy to control serum phosphorus concentrations. Most phosphate binders
have a high daily pill burden, which may reduce treatment adherence and impair phosphorus control. Sucroferric oxyhydroxide is a potent iron-based phosphate binder approved for use in dialysis-dependent patients in 2013. A randomized
controlled trial of sucroferric oxyhydroxide demonstrated its efficacy for reduction of serum phosphorus with a lower pill
burden than sevelamer carbonate. Clinical trials carefully select patients, monitor adherence, and routinely titrate medications to a protocol-defined goal. Consequently, trials may not reflect real-world use of medications. Since its approval, we
and others have performed retrospective and prospective analyses of sucroferric oxyhydroxide in real-world clinical practice in > 6400 hemodialysis and approximately 500 peritoneal dialysis patients in the USA and Europe. Consistent with the
clinical trial data, real-world observational studies have demonstrated that sucroferric oxyhydroxide can effectively reduce
serum phosphorus with a lower daily pill burden than most other phosphate binders. These studies have also shown sucroferric oxyhydroxide provides effective serum phosphorus control in different treatment settings, including as monotherapy
in phosphate binder-naïve patients, in patients switching from other phosphate binders, or when used in combination with
other phosphate binders. These observational studies indicate a favorable safety and tolerability profile, and minimal, if any,
systemic iron absorption. This article reviews the key results from these observational studies of sucroferric oxyhydroxide
and evaluates its role in the management of hyperphosphatemia in clinical practice.
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Hyperphosphatemia is a frequent complication in patients
with dialysis-dependent chronic kidney disease [1]. Elevated
serum phosphorus is a major factor in the development of
secondary hyperparathyroidism, and is associated with
vascular calcification, increased cardiovascular events, and
higher mortality in dialysis patients [2–7]. Experimental
studies strongly suggest a causal role for hyperphosphatemia
for these clinical events [8].
While randomized controlled trials are lacking, large
observational cohort studies of dialysis patients have shown
that reduction of elevated serum phosphorus is associated
with improved survival [9, 10]. Guideline organizations
provide different targets for phosphorus control in dialysis
patients. The National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative guidelines [11] recommend
targeting a serum phosphorus of 3.5–5.5 mg/dl, while the
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Kidney Disease Improving Global Outcomes guidelines
[12] recommend lowering phosphorus toward “normal”
(< 4.6 mg/dl).
The majority of dialysis patients need treatment with
oral phosphate binders (PBs) to reduce gastrointestinal (GI)
absorption of phosphate and achieve serum phosphorus control [13]. Data from cross-sectional studies show that dialysis patients treated with PB therapy have significantly lower
mortality rates, compared with those who do not receive
PBs, even after propensity score matching and adjustment
for nutritional status [14–16]. Nevertheless, more than a
third of dialysis patients in the USA and Europe have serum
phosphorus concentrations above 5.5 mg/dl [17, 18].
Several PBs are currently available. Most PBs have a high
daily pill burden [19, 20], which may lead to poor adherence.
Poor PB adherence associates with higher serum phosphorus [21, 22]. An analysis of global data showed that 45% of
dialysis patients skipped taking their PB at least once in the
previous month, and 57% of US patients reported doing so
[22]. Key attributes of an optimal PB therapy include a high
phosphate-binding capacity across the pH range in the GI
tract, a low daily pill burden, minimal systemic absorption,
a good safety profile, high tolerability, and low cost [23].
Sucroferric oxyhydroxide (SO; V
 elphoro®) is a potent,
iron-based PB with a low daily pill burden, approved for the
control of serum phosphorus concentrations in patients with
chronic kidney disease undergoing dialysis [24, 25]. SO is
approved in the USA (2013), Europe (2014), and several
other countries. The product is composed from a mixture
of sucrose, starches, and the active moiety, polynuclear
iron(III)-oxyhydroxide. It is formulated as chewable, berryflavored tablets, which each contain 500 mg of iron. The
recommended starting dose of SO is 3 tablets (1500 mg)
per day, taken as 1 tablet (500 mg) 3 times daily with meals.
The dose of SO should be titrated in increments of 1 tablet
(500 mg) each day every 2–4 weeks until the target serum
phosphorus concentration is reached. The maximum daily
dose of SO evaluated in clinical studies was 6 tablets per
day (3000 mg) [25]. The SO 24-week Phase 3 clinical trial,
conducted in 1,055 hemodialysis and peritoneal dialysis
patients, demonstrated that SO was non-inferior to sevelamer
carbonate (“sevelamer”) for reduction of serum phosphorus
after 12 weeks, with a lower daily pill burden (2.8 pills/day
vs 7.6 pills/day) and better treatment adherence (82.6% vs
77.2% at Week 24) [26]. These reductions in serum phosphorus with SO were also sustained during the subsequent
28-week extension study [27]. During the Phase 3 trial and
its extension study, the most commonly reported adverse
events with SO were mild transient diarrhea and discolored
feces [26, 27].
Subgroup analyses of the Phase 3 data showed a similar long-term efficacy and safety profile for SO in patients
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who were undergoing peritoneal dialysis [28] and in African
American patients [29].
A post hoc analysis of iron-related parameters showed
a small but statistically significant increase in transferrin
saturation (TSAT) with SO, compared with sevelamer, at
24 weeks (+ 4.6% vs + 0.6%, p = 0.003), while the increase
of mean serum ferritin did not differ significantly between
SO and sevelamer (+ 119 ng/ml vs + 56 ng/ml, respectively,
p = not significant) [30]. The small increase in TSAT with
SO use suggests a low level of iron absorption. Consistent
with this finding, an Fe-59 radiolabeled-SO iron absorption
study in eight hemodialysis patients reported median uptake
of 0.02% of elemental iron present in SO (range 0–0.04%)
[31]. In the Phase 3 trial, use of intravenous (IV) iron was
common in both study arms (> 70%) and was likely the
major driver for most changes in iron-related parameters
[30]. Although the use of IV iron and erythropoiesis-stimulating agents (ESAs) was similar at baseline, IV iron use was
slightly lower in the SO arm than in the sevelamer arm over
Weeks 1 to 24 (69.3% vs 75.8%, respectively) and during
Weeks 24 to 52 (63.0% vs 68.3%, respectively). Concomitant
ESA therapy was also lower in the SO arm vs the sevelamer
arm during Weeks 1–24 (83.2% vs 86.8%) and Weeks 24 to
52 (80.8% vs 88.1%; p = 0.0252) [30].
A post hoc analysis of changes in mineral bone disorder markers during the Phase 3 trial data pooled the groups
because SO and sevelamer had similar effects [32]. After
1 year of treatment, median intact fibroblast growth factor-23
(FGF-23) decreased by 64% (p < 0.001 vs baseline). Serum
calcium concentrations remained unchanged during this
period. The bone formation markers, bone-specific alkaline
phosphatase, and osteocalcin increased, which may indicate
a benefit of SO and sevelamer therapy on bone metabolism
[32].
Prospective clinical trials of SO were conducted in specialist centers, enrolled select dialysis patients, and continually monitored drug adherence and titrated medications to
target phosphorus. These studies differ from the real-world
setting, limiting external validity of clinical trial findings.
To assess aspects of routine clinical use of SO, a series
of observational studies were performed in the USA and
Europe since 2013 (summarized in Table 1). The key results
from these observational studies of SO are presented below.

Real‑world effectiveness of sucroferric oxyhydroxide
Several effectiveness studies have utilized medical databases
of large US and European dialysis organizations to retrospectively analyze de-identified data for in-center dialysis
patients prescribed SO as part of routine care. The effectiveness of SO has also been evaluated prospectively by
VERIFIE (Velphoro Evaluation of Real-lIfe saFety,

USA

USA

Coyne et al. (2020) [35]

USA

Location of
study population

Kendrick et al. (2019) [34]

FKC database studies
Coyne et al. (2017) [33]

Author

Retrospective comparative cohort study
SO follow-up: 24 months

Retrospective cohort study
SO follow-up: 12 months

Retrospective cohort study
SO follow-up: up to 6 months

Summary of key results

% patients with sP ≤ 5.5 mg/dl (BL vs Months
3 and 6)
•SO 1–3: 13.9% vs 26.1% at Month 3
(p < 0.001)
•SO 4–6: 15.6% vs 30.4% at Month 6
(p < 0.0001)
PB pill burden (BL vs Months 3 and 6)
•SO 1–3: 9.6 vs 3.8 pills/day (p < 0.001)
•SO 4–6: 9.7 vs 4.0 pills/day (p < 0.0001)
% patients with sP ≤ 5.5 mg/dl (BL vs Q1 − Q4)
•530 adult, in-center HD patients switched
•Overall cohort: 17.7% vs 24.5 − 36.4%
to SO monotherapy from another PB. All
(p < 0.0001)
patients were required to have 12 months of
•African Americans: 14.3% vs 23.0 − 34.1%
uninterrupted SO prescriptions
(p = 0.004)
•Subgroup analyses were also performed for
•Hispanics: 18.4% vs 28.7 − 39.1% (p < 0.02 for
African American (n = 217) and Hispanic
Q1, Q3, Q4)
(n = 87) patients
PB pill burden (BL vs Q1 − Q4)
•Overall cohort: 8.5 vs 4.3 pills/day (p < 0.0001)
•African Americans: 8.9 vs 4.1–4.5 pills/day
(p < 0.0001)
•Hispanics: 8.9 vs 4.1–4.4 pills/day (p < 0.0001)
% patients with sP ≤ 5.5 mg/dl (BL vs Q1 and
•Patients who received 2 years of uninterQ8)
rupted SO therapy (mSO, n = 222) were
compared with patients who discontinued SO •mSO: 20.7% vs 36.9% and 45.0% (p < 0.001)
therapy (dSO, n = 596) within 90 days of first •dSO: 16.1% vs 29.0% and 31.9% (p < 0.001)
PB pill burden (BL vs Q8)
prescription and switched to other PBs
•mSO: 7.5 vs 4.4 pills/day (p < 0.001)
•dSO: 9.1 vs 9.3 pills/day (p = 0.3)
All-cause hospitalizations
•mSO patients had 35.6 fewer hospitalizations
per 100 patient-years (incidence rate ratio,
0.75 [95% CI, 0.58–0.96])
•1,029 adult in-center HD patients switched
to SO monotherapy from another PB and
received up to 6 months of SO therapy
•2 × patient cohorts analyzed:
–1–3 months of SO prescription (SO 1–3;
n = 1,029)
–4–6 months of SO prescription (SO 4–6;
n = 424)

Study design and SO follow-up duration Patient population analyzed

Table 1  Overview of key real-world studies evaluating sucroferric oxyhydroxide in dialysis patients
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DaVita Inc. database
Gray et al. (2019) [41]
USA

Kalantar-Zadeh et al. (2018) [40] USA

Retrospective cohort study
SO follow-up: up to 6 months

Retrospective cohort study
SO follow-up: up to 6 months

Retrospective cohort study
SO follow-up: up to 12 months

Molony et al. (2020) [38]

USA

Retrospective cohort study
SO follow-up: 24 months

Kalantar-Zadeh et al. (2019) [37] USA

•490 adult in-center HD patients converted to
SO monotherapy from another PB therapy
•A subgroup analysis was performed on 30
patients not using the DaVita pharmacy’s
automated refill-management services to
evaluate changes in PB medical possession
ratio following the switch to SO

•258 adult peritoneal dialysis patients prescribed SO monotherapy for up to 6 months

•234 adult in-center HD patients prescribed
SO in combination with other PB(s) for at
least 120 days

•59 adult in-center PB-naïve HD patients who
initiated SO as a first-line PB therapy within
their first year of dialysis treatment

•172 adult in-center PB-naïve HD patients
who initiated SO as a first-line PB therapy
•A subgroup analysis was performed on 44
patients who were new to dialysis treatment
(i.e. within their first year of dialysis)

Study design and SO follow-up duration Patient population analyzed

Retrospective cohort study
SO follow-up: 12 months

Location of
study population

Kalantar-Zadeh et al. (2018) [36] USA

Author

Table 1  (continued)

% patients with sP ≤ 5.5 mg/dl (BL vs follow-up)
•22.0% vs 30,0% (p < 0.001)
PB pill burden (BL vs follow-up period)
•10.8 vs 5.5 pills/day (p < 0.001)
Mean PB medication possession ratio (BL vs
Month 6)
•0.68 vs 0.80 (p = 0.01)

% patients with sP ≤ 5.5 mg/dl (BL vs Q1 − Q8)
•37% vs 42 − 49% (p < 0.001)
SO pill burden (Q1 − Q8)
•4.4 − 5.1 pills/day
% patients with sP ≤ 5.5 mg/dl (BL vs Q1 − Q4)
•19.0% vs 33–40% (p < 0.001)
PB pill burden (BL vs Q1 − Q4)
•12.3 vs 15.8 − 12.3 pills/day (p < 001 at Q1;
p = 0.9 at Q4)
% patients with sP ≤ 5.5 mg/dl (BL vs Month 6)
•26.0% vs 44.4% (p < 0.001)
PB pill burden (BL vs Month 6)
•10.0 vs 4.3 pills/day (p < 0.0001)

% patients with sP ≤ 5.5 mg/dl (BL vs Q1 − Q4)
•Overall cohort (n = 172): 23.7% vs
32.6 − 38.8% (p < 0.0001)
•New to dialysis (n = 44): 31.8% vs 40.9 − 52.4%
(p < 0.0001)
SO pill burden (Q1 − Q4)
•Overall cohort (n = 172): 3.9 − 4.1 pills/day
(p < 0.0001)
•New to dialysis (n = 44): 3.7 − 3.9 pills/day
(p < 0.0001)

Summary of key results
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Europe

Location of
study population

Non-interventional, prospective, postauthorization safety study
SO follow-up: up to 36 months

Retrospective cohort study
SO follow-up: up to 12 months

% of patients with sP ≤ 5.5 mg/dl (BL vs
Q1–Q4)
•Overall cohort: 41.3% vs 56.2 − 62.7%
(p < 0.0001)
•SO subgroup: 49.5% vs 62.5–75.2%
(p < 0.0001 for Q1, Q2, Q3)
•PB → SO subgroup: 58.5% vs 53.6–68.0 (n.s.)
•PB + SO subgroup: 38.1% vs 53.9–60.9%
(p < 0.0001 Q1–Q4);
PB pill burden (BL vs Q1–Q4)
•Overall: 6.3 vs 5.0 − 5.3 pills/day
•SO subgroup: 0 vs 2.1 − 2.3 pills/day
•PB → SO subgroup: 2.1 vs 2.6 − 2.8 pills/day
•PB + SO subgroup: 6.5 vs 6.0 − 6.2 pills/day
Safety results
•531/1,365 patients (39%) had ≥ 1 ADR during
SO treatment
•Most frequent ADRs: diarrhea (14% patients)
and discolored feces (9% patients), mainly
mild/moderate in severity
•Fatal events occurred in 119 patients (8.7%);
none were considered treatment-related
•Small increases in mean serum ferritin and
TSAT:
-Ferritin: 377 µg/l at BL up to 444 µg/L at
Month 24 (Δ BL: + 75 µg/l; p < 0.05)
-TSAT: 26.1% at BL up to 29.0% at Month
3 (Δ BL: + 2.1%; p < 0.001)
Effectiveness results
% of patients with sP ≤ 5.5 mg/dl (BL vs followup period)
•30% vs 47 − 63% (p < 0.001)
SO pill burden
•Overall cohort: 2.3 SO pills/day
•SO monotherapy subgroup: 2.5 SO pills/day
•SO combination subgroup: 2.3 SO pills/day

•1,402 dialysis patients from seven European
countries (France, Germany, Greece, Italy,
Portugal, Spain, and United Kingdom) prescribed SO as part of routine clinical practice
•1,365 patients were eligible for safety analysis
and 1,322 patients were evaluable for SO
effectiveness analysis

Summary of key results

•1,096 HD patients from five European countries (France, Italy, Portugal, Russia, Spain)
newly prescribed SO for up to 1 year as part
of routine clinical practice
•Subgroup analysis was performed on the following patient subgroups
–188 PB-naïve patients treated with SO monotherapy (SO subgroup)
–53 PB-pretreated patients switched to SO
monotherapy (PB → SO subgroup)
–796 PB-pretreated patients receiving SO in
addition to another PB (PB + SO subgroup)

Study design and SO follow-up duration Patient population analyzed

ADR, adverse drug reaction; BL, baseline; FKC, Fresenius Kidney Care; HD, hemodialysis; n.s., not statistically significant; PB, phosphate binder; SO, sucroferric oxyhydroxide

VERIFIE post-authorization study
Vervloet et al. (2020) [43]
Europe

FMC EuCliD® database
Ramos et al. (2020) [42]

Author

Table 1  (continued)
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effectIveness, and adherencE)—a post-authorization safety
study of SO in European dialysis patients.

Fresenius Kidney Care database studies
SO monotherapy in hemodialysis patients switched
from other PBs
The effect of switching hemodialysis patients from other PBs
to SO monotherapy was evaluated by several retrospective
analyses of the Fresenius Kidney Care (FKC) database.
An initial study analyzed data for 1029 adult in-center
hemodialysis patients switched to SO monotherapy for up
to 6 months [33]. Most patients switched to SO had poor
phosphorus control. In total, 424 patients received > 3 consecutive months of SO prescriptions. The proportion of this
group achieving in-target serum phosphorus (≤ 5.5 mg/
dl) increased approximately two-fold by the end of the
6-month follow-up period (from 15.6% at baseline to 30.4%,
p < 0.0001), while daily PB pill burden fell from 9.7 to 4.0
pills/day (p < 0.0001) [33].
A subsequent longer-term study [34] evaluated 530 incenter hemodialysis patients switched to SO monotherapy,
receiving 12 months of continuous prescriptions. Comparisons in PB pill burden, serum phosphorus, and other clinical
parameters were made between baseline (the 91-day period
prior to SO treatment) and consecutive 91-day intervals of
SO treatment (Q1–Q4). PBs received by patients during the
baseline period included sevelamer (59.8%), calcium acetate
(CaAc) (27.6%), lanthanum carbonate (7.9%), or magnesium
carbonate (0.4%), or a switch between these agents (4.3%).
After the switch to SO, mean serum phosphorus progressively decreased (from 6.82 mg/dl at baseline to, respectively, 6.54 mg/dl, 6.37 mg/dl, 6.25 mg/l, and 6.19 mg/
dl at Q1, Q2, Q3, and Q4; p < 0.0001 vs baseline). The
percentage of patients with serum phosphorus ≤ 5.5 mg/
dl increased approximately two-fold, rising from 17.7%
at baseline to 24.5%, 30.5%, 36.4%, and 36.0% at Q1, Q2,
Q3, and Q4, respectively (p < 0.0001). Mean daily PB pill
burden declined by approximately 50%, from 8.5 pills/day
at baseline to between 4.0 and 4.3 pills/day during Q1–Q4
(p < 0.0001) [34].
A stratified analysis found consistent reductions in serum
phosphorus concentrations and increases in the proportion of
patients achieving serum phosphorus ≤ 5.5 mg/dl, irrespective of baseline PB therapy [34]. For patients who switched
from sevelamer to SO (n = 317), mean serum phosphorus
decreased from 6.77 mg/dl at baseline to 6.14 mg/dl by Q4
(p < 0.0001). Marked reductions from baseline in serum
phosphorus were also observed for patients switching from
CaAc to SO (n = 146) (from 6.90 mg/dl to 6.31 mg/dl by
Q4; p < 0.0001), and those switching from lanthanum carbonate to SO (n = 42) (from 6.71 mg/dl to 5.93 mg/dl by
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Q4; p < 0.0001). Large reductions (> 50%) in PB pill burden were observed among patients who switched from sevelamer and CaAc. Those switching from sevelamer received
8.9 sevelamer pills/day at baseline vs 4.0–4.4 SO pills/
day during Q1–Q4 (p < 0.0001). Patients switching from
CaAc received 8.9 CaAc pills/day at baseline vs 3.9–4.0 SO
pills/day during Q1–Q4 (p < 0.0001). Pill burden remained
unchanged for patients who switched from lanthanum carbonate (4.4 lanthanum pills/day at baseline vs 4.5–4.7 SO
pills/day; p = 0.56), although the improvement in phosphorus
control with SO paralleled the results for the other PBs.
This study also examined the effectiveness of 1 year of
SO monotherapy in the subgroups of Black/African American (n = 217) and Hispanic patients (n = 87) [34]. Switching
to SO among Black/African American patients increased the
proportion of those achieving serum phosphorus ≤ 5.5 mg/
dl from 14.3% at baseline to 23.0–34.1% during Q1–Q4
(p = 0.004), while PB pill burden fell from 8.9 pills/day at
baseline to 4.1–4.5 SO pills/day during Q1–Q4 (p < 0.0001).
Similarly, the proportion of Hispanic patients achieving
serum phosphorus ≤ 5.5 mg/dl increased from 18.4% at baseline to between 28.7% and 39.1% during Q1–Q4, and PB pill
burden declined from 8.9 pills/day at baseline to 4.1–4.4 SO
pills/day (all p < 0.0001).
Small reductions in corrected calcium (9.25 mg/dl at
baseline vs 9.10 mg/dl at Q4; p < 0.0001) and increases in
serum intact parathyroid hormone (611 pg/ml at baseline vs
643 pg/ml at Q4; p = 0.16) were observed. The extent of the
changes in iPTH were similar to those observed in the Phase
3 trial and its extension study [26, 27]. As approximately one
third of patients were on calcium-based PBs prior to switching, the withdrawal of calcium loading and progression of
hyperparathyroidism may account for these small changes.
The previously described retrospective database analyses used patients’ own data prior to switching to SO, but a
concurrent control group was lacking. To address this issue,
a retrospective cohort study of hemodialysis patients that
utilized a novel design was conducted in order to evaluate
the long-term real-world effectiveness of SO, compared with
other routinely prescribed PBs [35].
In this study, adult in-center hemodialysis patients maintained on SO therapy (designated “mSO”) for 2 years were
compared with an active control group of patients who discontinued SO (“dSO”) within 90 days of their initial prescription and were switched back to other PB(s). All patients
had serum phosphorus laboratory values and PB therapy
recorded at baseline (3-month period prior to SO initiation)
and the final quarter (Q8) of the 2-year follow-up period
(Q1–Q8). Key outcomes assessed included achievement of
the serum phosphorus target (≤ 5.5 mg/dl) and PB pill burden [35].
A total of 818 patients (222 mSO and 596 dSO) were
included in the analysis [35]. The proportion of patients
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achieving serum phosphorus ≤ 5.5 mg/dl during Q1–Q8
increased significantly both in the mSO group [from 20.7%
at baseline vs 36.9% at Q1 to 45.0% at Q8 (p < 0.001)] and in
the dSO group [16.1% at baseline vs 29.0% at Q1 to 31.9%
at Q8 (P < 0.001)] (Fig. 1). In the mSO group, 45% achieved
serum phosphorus ≤ 5.5 mg/dl at Q8 with 3.1 fewer pills/
day, compared with baseline (7.5 vs 4.4 pills/day; p < 0.001),
while 31.9% of dSO patients achieved serum phosphorus ≤ 5.5 mg/dl at Q8 with an unchanged pill burden (9.1
vs 9.3 pills/day; p = 0.3). Over 2 years of follow-up, mean
serum phosphorus decreased more in the mSO group than
in the dSO group (− 0.66 mg/dl vs − 0.45 mg/dl; p = 0.014).
Mean PB pill burden also decreased in the mSO group (8.5
to 5.1 pills/day; p < 0.001), but no change was observed in
the dSO group (11.6 to 10.9 pills/day; p = 0.2) (Fig. 1). To
evaluate the potential bias resulting from SO discontinuation during follow-up, a sensitivity analysis of data for 3047
patients who had received less than 2 years of SO therapy
was also performed. These findings confirmed that greater
serum phosphorus reductions were achieved with SO than
with other PBs. Significant reductions from baseline in
serum calcium and small but significant increases in parathyroid hormone were similarly observed in the mSO and
dSO groups during the 2-year follow-up period [35].
Overall, this 2-year retrospective comparative database
showed patients maintained on SO therapy for 2 years had
a greater likelihood of achieving target serum phosphorus

Fig. 1  Serum phosphorus control and phosphate binder pill burden
among maintenance sucroferric oxyhydroxide (mSO) and discontinued SO (dSO) patients at baseline and during the 2-year follow-up

881

concentrations and used 50% fewer PB pills/day, compared
with those switched to other routinely prescribed PBs [35].
PB‑naïve patients prescribed SO monotherapy
A retrospective database study of 172 adult PB-naïve incenter hemodialysis patients prescribed SO therapy for
12 months (Q1–Q4) showed significant increases in the
proportion achieving serum phosphorus ≤ 5.5 mg/dl, from
23.7% at baseline to 32.6–38.8% during Q1–Q4 (p < 0.0001)
[36]. The mean pill burden per quarter ranged from 4.0 to
4.1 SO pills/day. A subgroup analysis of 44 patients who
were within their first year of dialysis also found a significant
increase in the percentage of patients achieving serum phosphorus ≤ 5.5 mg/dl on SO therapy, from 31.8% at baseline to
between 40.9 and 52.4% during Q1–Q4 (p < 0.0001).
A longer-term retrospective study assessed a cohort
of 59 incident hemodialysis patients in their first year of
dialysis who were prescribed SO monotherapy for 2 years
(Q1–Q8) [37]. Treatment with SO was associated with a
significant reduction in serum phosphorus, from 6.14 mg/
dl to 5.49 mg/dl by Q8 (p < 0.0001), while the proportion of
patients achieving serum phosphorus ≤ 5.5 mg/dl was 37%
at baseline, 64% after 1 year (Q4) and 49% after 2 years (Q8)
(p < 0.001 baseline vs Q1 − Q8 follow-up). Mean SO pill
burden ranged from 4.4 to 5.1 SO pills/day.

period. Baseline % patients in-range: 20.7% (mSO), 16.1% (dSO);
baseline serum phosphorus: 6.61 mg/dl (mSO), 6.8 mg/dl (dSO);
baseline phosphate binder pills/day: 8.5 (mSO), 11.6 (dSO)
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It should be acknowledged that both of these studies
included a relatively small number of patients and have only
been published in congress abstract form and not undergone
peer review [36, 37].
SO therapy in combination with other PBs
The effects of SO prescribed with other PBs were evaluated by a retrospective study of 234 in-center hemodialysis
patients [38]. Patients received ≥ 120 days of prescriptions
of SO with other PB therapies, including CaAc, lanthanum
carbonate and sevelamer, for up to 1 year. For most patients
in the cohort (n = 196, 84%), SO was added to their baseline
PB therapy, while the remainder either received SO along
with a different PB(s) to their baseline regimen (n = 22,
9%), or were newly initiated on PB combination therapy
with SO (n = 16, 7%). In the overall study cohort, use of SO
in combination with other PBs was associated with significant reductions in serum phosphorus (6.7 mg/dl at baseline
vs 6.2–6.3 mg/dl during Q1–Q4; p < 0.001) and significant
increases in the proportion of patients with serum phosphorus ≤ 5.5 mg/dl (19% baseline vs 33–40% during Q1–Q4;
p < 0.001). Total PB pill burden initially increased from 12.3
pills/day at baseline to 15.8 pills/day at Q1 (p < 0.001) following the addition of SO treatment. However, the number
of non-SO PB pills were down-titrated over time, so that
by Q4, the mean total PB pill burden was 12.3 pills/day
(baseline vs Q4, p = 0.9). The mean SO pill burden during the 1-year follow-up period ranged from 4.0 pills/day
at Q1 to 4.6 pills/day at Q4. Subgroup analysis of patients
who received SO in addition to their baseline PB (n = 196)
showed that addition of SO to CaAc (n = 54) or sevelamer
(n = 94) was associated with ≥ 2.5-fold increases in the proportion of patients achieving serum phosphorus ≤ 5.5 mg/
dl (p < 0.001). Overall, this study shows that addition of SO
to other PB regimens improves the proportion of patients
achieving phosphorus goal, but does not decrease PB pill
burden [38].
Effect of SO monotherapy on serum albumin
and nutritional parameters
Improvements in phosphorus control with conversion to SO
may permit or even motivate patients to increase their protein intake, which could be beneficial to the patient despite
mitigating the phosphorus reduction by SO. To explore
whether this might occur, the impact of SO therapy on
serum albumin and other nutritional parameters was evaluated by a retrospective analysis of data for 79 adult in-center
hemodialysis patients with hypoalbuminemia (≤ 3.5 g/dl)
who were switched to SO for a minimum of 1 year [39]. A
matched reference group of patients without hypoalbuminemia at baseline (> 3.5 g/dl; n = 79) who were switched to SO
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was also evaluated [39]. The results showed that both hypo
albuminemic and non-hypoalbuminemic patients switched
to SO achieved reductions in serum phosphorus (– 0.40 g/dl
and – 0.51 g/dl, respectively) and daily PB pill burden (by
45.7% and 45.1%, respectively). Mean serum albumin concentrations among non-hypoalbuminemic patients remained
largely unchanged during the SO follow-up period (4.03 g/
dl at baseline vs 3.97–4.01 g/dl during Q1–Q4; p = non-significant). In contrast, significant increases in serum albumin
concentrations during SO therapy were seen in hypoalbuminemic patients (from 3.41 to 3.50 g/dl during the 6-month
baseline period [− Q1 and − Q2] vs 3.69–3.74 g/dl during
Q1–Q4; p < 0.0001), together with prolonged improvements
in other nutritional parameters, including increases in normalized protein catabolic rate, pre- and post-dialysis weight,
and serum creatinine [39]. These findings suggest that treatment with SO may enable hemodialysis patients to increase
their intake of dietary protein.
Effectiveness of SO in peritoneal dialysis patients
A retrospective database analysis evaluated 258 adult US
peritoneal dialysis patients prescribed SO monotherapy for
up to 6 months [40]. At baseline (3-month period prior to
SO prescription), patients’ mean serum phosphorus was
6.59 mg/dl, and 74% had serum phosphorus concentrations > 5.5 mg/dl. During the 6-month SO treatment period,
the proportion of patients achieving serum phosphorus ≤ 5.5 mg/dl increased from 26.0% at baseline to 44.4%
after 6 months (p < 0.001). Mean PB pill burden decreased
more than two-fold after patients switched to SO, from
10 PB pills/day at baseline to 4.3 SO pills/day during the
follow-up period (p < 0.0001).

DaVita Inc. database study
If a reduced PB pill burden increases adherence, patients
might request prescription refills more regularly. To assess
for this effect, an analysis was performed using electronic
health records from the DaVita Inc. database and pharmacy
service to evaluate PB pill burden, adherence, and serum
phosphorus control in 490 prevalent in-center hemodialysis
adults who had switched to SO therapy from other PB(s) as
part of routine care [41]. The 6 months prior to SO prescription was designated as baseline and the 6-month period after
the first SO prescription as follow-up.
As observed in studies of the FKC hemodialysis patient
population, switching to SO therapy was associated with a
significant reduction from baseline in mean PB pill burden
from 10.8 pills/day to 5.5 pills/day (p < 0.001), and increases
in the proportion of patients achieving serum phosphorus ≤ 5.5 mg/dl from 22.0 to 30.0% (p < 0.001) [41].
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A novel feature of this study was its evaluation of
whether switching to SO from other PB(s) was associated
with improved adherence to therapy, based on changes in
medical possession ratio (MPR) for 30 patients who were not
enrolled in the automated prescription refill service [41]. In
these patients, mean total PB MPR increased significantly
over time, from 0.68 at baseline to 0.80 during SO follow-up
(p = 0.01), supporting that switching to SO was associated
with improved treatment adherence. Improvements in MPR
suggest better adherence to SO may be related to lower pill
burden and drive the observed improvements in phosphorus.

Fresenius Medical Care EuCliD® database study
A retrospective study evaluated the real-world effectiveness
of SO in European hemodialysis patients, utilizing data from
the EuCliD® database to analyze a cohort of hemodialysis
patients from five European countries who were prescribed
SO for up to 1 year [42]. Serum phosphorus and PB pill burden of the overall cohort (n = 1,096) were compared between
a 3-month baseline period prior to SO initiation and four
quarterly periods of SO therapy (Q1 − Q4). In addition, three
patient subgroups were separately analyzed: (1) PB-naïve
patients treated with SO monotherapy (SO; n = 188); (2) PBpretreated patients switched to SO monotherapy (PB → SO;
n = 53); and (3) PB-pretreated patients receiving SO added
to another PB (PB + SO; n = 796).
In the overall cohort, serum phosphorus decreased significantly from 5.83 mg/dl at baseline to 5.48–5.24 mg/dl during Q1–Q4 (p < 0.0001 vs baseline) [42]. The proportion of
patients with serum phosphorus ≤ 5.5 mg/dl increased from
41.3% at baseline to between 56.2 and 62.7% during Q1–Q4
(p < 0.0001 vs baseline). The total PB pill burden decreased
from 6.3 pills/day at baseline to between 5.0 and 5.3 pills/
day over the 1-year SO treatment period.
In the subgroup analysis, the proportion of patients
achieving serum phosphorus ≤ 5.5 mg/dl increased to the
greatest extent in the SO subgroup (from 49.5% at baseline to 62.5–75.2% during Q1–Q4; p < 0.0001 for Q1, Q2,
Q3) and in the PB + SO subgroup (from 38.1% at baseline
to 53.9–60.9% during Q1–Q4; p < 0.0001 for all quarters) [42]. There were no statistically significant changes
in the proportion of patients achieving serum phosphorus ≤ 5.5 mg/dl in the PB → SO group. In the PB + SO group,
the total mean number of PB pills prescribed during SO
follow-up remained unchanged (6.5 pills/day at baseline vs
6.0 − 6.2 pills/day during Q1–Q4), while daily PB pill burden marginally increased for PB → SO patients, from 2.1
pills/day at baseline to between 2.6 and 2.8 pills/day. The
mean SO pill burden was relatively low across all subgroups
analyzed (2.1 − 2.8 pills/day).
Overall, the E
 uCliD® database analysis indicated that
administration of SO either as monotherapy to PB-naïve
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patients or as add-on therapy to an existing PB therapy regimen was associated with improvements in serum phosphorus control and a low daily pill burden [42].

VERIFIE post‑authorization safety study
The long-term effectiveness of SO for serum phosphorus
control was prospectively evaluated by the VERIFIE postauthorization safety study [43]. VERIFIE enrolled 1406
adult hemodialysis or peritoneal dialysis patients from seven
European countries, all of whom had been prescribed SO in
accordance with the product label. The planned follow-up
period for each patient was 12–36 months.
In total, 1322 patients were included in the effectiveness
analysis: the majority (n = 1169; 88.4%) were receiving
hemodialysis and 153 (11.6%) undergoing peritoneal dialysis [43]. SO therapy was associated with significant reductions from baseline in mean serum phosphorus (6.3 mg/dl
vs 5.3 mg/dl at Month 30; Δ baseline: − 1.0 mg/dl; p < 0.01)
(Fig. 2a). The proportion of patients achieving serum phosphorus ≤ 5.5 mg/dl increased from 30% at baseline to
between 47 and 63% during follow-up (Fig. 2b). The mean
daily SO dose during the overall observation period was
2.3 SO pills/day. Forty-five percent of patients in VERIFIE
were prescribed SO in combination with other PBs. A stratified analysis showed similar serum phosphorus reductions
among patients who received SO in combination with other
PBs and those who received SO monotherapy. The mean
daily SO pill burden during the observation period was also
similar between the SO monotherapy and SO combination
groups (2.5 pills/day and 2.3 pills/day, respectively) [43].

Effect of SO therapy on hospitalizations
and potential cost‑savings
Treatment with SO may be associated with a reduced rate of
hospitalizations, compared with other PB therapies.
An observational study analyzed data from 24 endstage renal disease seamless care organizations in the
USA to assess hospital admission rates of dialysis patients
prescribed different PB therapies over a 3-year period
(2016–2018) [44]. The hospitalization rate (per 100-member months [MM]) was lower among patients treated with
SO (7.97 per 100-MM) compared with those treated with
sevelamer (10.52 per 100-MM), CaAc (11.28 per 100-MM),
ferric citrate (9.54 per 100-MM), or lanthanum carbonate
(8.86 per 100-MM) [44].
The effect of SO monotherapy vs other routinely prescribed PBs on the incidence of hospital admissions in US
hemodialysis patients was evaluated by the 2-year retrospective comparative cohort study by Coyne and colleagues
[35]. Patients maintained on SO therapy for 2 years had 35.6
fewer hospitalizations per 100 patient-years than patients
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Fig. 2  VERIFIE study: serum
phosphorus control during the
observation period (full analysis
set; N = 1322). A Mean ± SD
phosphorus concentrations
and changes from baseline
over time. B Proportion of
patients with serum phosphorus ≤ 5.5 mg/dl. **p < 0.01,
***p < 0.001 vs baseline. On
panel A, bars show mean values
and whiskers represent standard
deviations. SD, standard deviation; sP, serum phosphorus

who discontinued SO within 90 days and switched to other
PBs [incidence rate ratio = 0.75 (95% confidence interval
0.58–0.96)]. Using in-patient expenditure data for hemodialysis patients from the 2018 US Renal Data System Annual
Data Report, use of SO instead of other PBs was associated with a potential annual cost saving of $566,295 per
100 patients [35].
A subsequent economic analysis applied the hospitalization data from the study [35] to potential hospitalization
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cost-savings with SO vs other PBs in five European countries
[45]. The results showed that treatment with SO is likely
to result in inpatient cost-savings of €118,922, €451,714,
€227,940, €125,750, and €314,282 per 100 patient-years
lived in, respectively, France, Germany, Italy, Spain, and
the UK [45].
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Safety and tolerability data
for SO in real‑world settings
VERIFIE post‑authorization safety study
Primary safety endpoints of VERIFIE included the incidence
of adverse drug reactions (ADRs) and medical events of
special interest (MESIs) (defined as adverse events of GI
bleeding, diarrhea, and iron accumulation irrespective of
their relationship to SO) [43]. Physicians’ evaluations of the
potential masking effect of the stool discoloration due to SO
treatment on GI bleeding diagnosis, iron-related parameters
(ferritin, TSAT, and hemoglobin), and fatal events were also
assessed.
In total, 1,365 patients were included in the safety analysis set. The mean observation period was 420 days, and 59%
of patients were treated with SO for 12 months or longer. A
total of 531 patients (39%) in the safety analysis set had ≥ 1
ADR during treatment with SO (Table 2). The most common
ADRs were GI disorders, mainly diarrhea and discolored
feces, reported by 194 (14%) and 128 (9%) patients, respectively. Serious ADRs were reported for 26 patients (2%).

Table 2  Adverse drug reactions occurring in ≥ 1.0% of patients by
system organ class and preferred term in the VERIFIE PASS study
System Organ Class
Preferred Term

Safety Analysis
Set (N = 1,365)
Patients, n (%)

Patients with at least 1 ADR
Gastrointestinal disorders
Diarrhea
Discolored feces
Abnormal feces
Constipation
Abdominal pain
Nausea
Soft feces
Vomiting
Dyspepsia
Injury, poisoning, and procedural complications
Off-label use
General disorders and administration-site conditions
Drug ineffective
Treatment noncompliance
Product issues
Product taste abnormal

531 (38.9)
436 (31.9)
194 (14.2)
128 (9.4)
48 (3.5)
40 (2.9)
38 (2.8)
36 (2.6)
20 (1.5)
17 (1.2)
16 (1.2)
59 (4.3)
29 (2.1)
56 (4.1)
26 (1.9)
15 (1.1)
24 (1.8)
23 (1.7)

All ADRs were coded based on MedDRA Version 22.0 terminology
into System Organ Class and Preferred Terms
ADR, adverse drug reaction; MedDRA, Medical Dictionary for Regulatory Activities; PASS, post-authorization safety study

Overall, 250 patients (18%) had ≥ 1 MESI during the study,
the most frequent of which were GI disorders [43].
A total of 217 patients (16%) reported diarrhea. It tended
to occur soon after SO initiation and was generally mild
(53%) or moderate (40%) in severity. In most patients, the
first event of diarrhea resolved within 2 weeks of initial
onset. These findings were consistent with those previously
reported in the Phase 3 study, in which diarrhea was mainly
mild and transient in nature [26, 27].
GI bleeding occurred in 38 patients while being treated
with SO during the study (46 events). Most patients (n = 32,
84%) had risk factors for GI bleeding, including medication (use of anticoagulant therapy), history of GI bleeding,
or medical conditions and/or disease with increased bleeding risk [43]. No clinically significant delays in GI bleeding diagnosis owing to SO-related stool discoloration were
reported during the study.
A total of 119 fatal events (8.7%) occurred during the
study, none of which were considered related to SO treatment. Overall, the VERIFIE study confirmed that SO has
a good safety and tolerability profile [43], consistent with
observations in the Phase 3 trial and its extension study [26,
27].

Impact of SO therapy on iron parameters
and anti‑anemia medication use
The effect of SO therapy on iron parameters and anti-anemia
medication use in the real-world setting has been evaluated
by several studies. In the VERIFIE study, SO therapy was
associated with small increases in mean serum ferritin (from
377 µg/l at baseline up to 444 µg/L at Month 24; Δ baseline: + 75 µg/l; p < 0.05) and TSAT (from 26.1% at baseline
up to 29.0% at Month 3; Δ baseline: + 2.1%; p < 0.001). A
subgroup analysis stratifying patients by concomitant IV/
oral iron use (yes vs no) indicated that increases in these
iron parameters were mainly driven by iron therapy use, as
ferritin values did not increase in the latter subgroup [43].
MESIs of iron overload were reported for two patients during the study. However, both were receiving concomitant
IV iron therapy, and one of them had an iron utilization
disorder [43].
Retrospective observational studies of both hemodialysis
and peritoneal patients have also reported small but significant initial increases in ferritin and TSAT during treatment
with SO [33–36, 41–43]. The findings are consistent with
the minimal iron absorption from SO reported in the Phase
3 trial and its extension [30].
Use of SO may result in a small reduction in overall IV
iron use. A decline in the usage and/or dose of IV iron or
ESA among patients treated with SO has been reported by
real-world studies in the USA and Europe [33–35, 42, 43].
These findings are consistent with the results of the Phase 3
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study and its extension, in which SO treatment was accompanied with a small reduction in the proportion of patients
receiving concomitant IV iron and ESA use over 1 year [30].

Limitations
This review has some limitations. First, it was a narrative
rather than systematic literature review, and therefore may
not have captured all published studies evaluating the use of
SO in real-word clinical practice. Second, several of the SO
studies described were retrospective in nature and used data
from electronic medical records, which were not specifically
collected for the purposes of clinical research. Consequently,
some variables of interest were not captured, including data
relating to SO tolerability, treatment adherence, reasons for
treatment initiation, and information relating to patients’
nutritional habits/dietary phosphate intake. Finally, it should
be acknowledged that the authors of this review also participated as investigators in some of the SO studies described
in the text.

Conclusions
Evidence from prospective randomized controlled trials and
real-world observational studies has demonstrated that SO
is an effective and well-tolerated PB therapy for control of
serum phosphorus concentrations in dialysis patients and is
associated with a low daily pill burden.
The effectiveness of SO therapy in the real-world clinical
setting has been extensively evaluated by a range of observational studies conducted in a large number of hemodialysis
(> 6400) and peritoneal dialysis (~ 500) patients in the USA
and Europe in both retrospective and prospective cohorts. In
line with the Phase 3 clinical trial program data, these studies have demonstrated that SO can effectively reduce serum
phosphorus with a lower daily pill burden than many other
commonly prescribed PBs, which may translate into better
treatment adherence. The studies have also shown that SO
is effective when prescribed in a variety of treatment settings, including as monotherapy among patients switching
from other PBs [33–35], as first-line therapy in PB-naïve
patients [36, 37], or when used in combination with other
PB therapies [38, 43].
It is important to note that the patients included in these
real-world studies were a selected group prescribed SO as
part of routine clinical practice and therefore may not be
representative of the overall dialysis patient population with
respect to the severity of their hyperphosphatemia. In the
US patient cohorts, initiation of SO therapy significantly
improved serum phosphorus control, but many patients did
not achieve target phosphorus concentrations (≤ 5.5 mg/
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dl). This observation illustrates the challenge of managing
hyperphosphatemia in the real-world setting and indicates
the need for a combined treatment approach. The use of SO
as part of an individualized, multipronged intervention in
conjunction with nutritional counseling, dialysis optimization, and the judicious use of vitamin D therapy, may further help improve serum phosphorus control in patients with
hyperphosphatemia. The safety profile of SO therapy, as
demonstrated in the clinical trials, was confirmed in the realworld setting by the prospective VERIFIE post-authorization
safety study, which included patients from > 1,300 patients
undergoing hemodialysis or peritoneal dialysis [43].
In summary, SO offers an effective and well-tolerated
treatment option for the control of serum phosphorus concentrations among dialysis patients with hyperphosphatemia
in the real-world clinical setting.
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